TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer
Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Oct 12, 2022
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
The TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer trial, also known as TOPCOP3, is studying how different types of supportive care can help older men with advanced prostate cancer. This includes evaluating a thorough health check-up and ongoing symptom monitoring over the phone. The goal is to see which approach works best, whether it's one of these methods, both, or neither, to improve the care of patients. The results will help researchers design larger studies in the future.
To participate, men must be at least 65 years old, have recently started or switched their cancer treatment, and be able to speak and understand English. They also need to have a working phone and be able to give their consent to join the study. Participants can expect to receive support and monitoring throughout the trial, which will help researchers learn more about the best ways to care for older men facing this challenging disease. It’s important to note that this study is currently recruiting participants, and it has strong backing from cancer support groups.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Starting an ARAT or started an ARAT within 2 weeks prior to being approached or switching ARATs due to progression or toxicity
- • 2. Diagnosed with mPC (castration-sensitive or resistant) or nmCRPC (non-metastatic castration-resistant prostate cancer)
- • 3. At least 65 years old
- • 4. Able to provide written informed consent
- • 5. Has a working telephone
- Exclusion Criteria:
- • 1. Unable to speak English (as contact with the nurse interventionist is via phone, not all outcome measures are available in multiple languages)
- • 2. Major neuropsychiatric abnormalities (severe depression or moderate-severe dementia)
- • 3. Life expectancy \<3 months as estimated by the oncologist
About University Health Network, Toronto
University Health Network (UHN), based in Toronto, is a leading academic health sciences center dedicated to advancing patient care through innovative research and education. As a prominent sponsor of clinical trials, UHN integrates cutting-edge scientific discoveries with clinical practice, facilitating the development of new therapies and treatment modalities. With a commitment to improving health outcomes, UHN collaborates with a diverse network of researchers, healthcare professionals, and industry partners, fostering an environment that prioritizes patient safety and ethical standards in clinical research. Through its extensive resources and expertise, UHN plays a pivotal role in transforming healthcare and enhancing the quality of life for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Patients applied
Trial Officials
Shabbir Alibhai, MD
Principal Investigator
UHN - Princess Margaret Cancer Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials